MARKET

GILD

GILD

Gilead Sciences
NASDAQ

Real-time Quotes | Nasdaq Last Sale

64.62
+1.39
+2.20%
After Hours: 64.85 +0.23 +0.36% 19:59 03/05 EST
OPEN
63.42
PREV CLOSE
63.23
HIGH
64.75
LOW
63.30
VOLUME
9.76M
TURNOVER
--
52 WEEK HIGH
85.97
52 WEEK LOW
56.56
MARKET CAP
81.20B
P/E (TTM)
1133.68
1D
5D
1M
3M
1Y
5Y
Gilead wins FDA approval for Yescarta in follicular lymphoma
Kite, a unit of Gilead Sciences (GILD), has announced that the FDA has granted approval for its T cell immunotherapy Yescarta (axicabtagene ciloleucel) for a certain category of adults with relapsed or
Seekingalpha · 1h ago
Why Is Gilead (GILD) Down 1.8% Since Last Earnings Report?
Zacks.com · 11h ago
Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults in Four-Year Data Presented at CROI
Gilead Sciences, Inc. (Nasdaq: GILD) today announced new, long-term data from open-label extensions (OLE) of two Phase 3 studies (Study 1489 and Study 1490)...
BusinessWire - BZX · 15h ago
Covid-19 Pill Shows Promise in Preliminary Testing
The antiviral reduced infectious virus in Covid-19 patients in a mid-stage study. Larger trials are under way exploring whether it prevents severe illness and death.
marketwatch.com · 22h ago
BRIEF-U.S. FDA Approves Yescarta For Relapsed Or Refractory Follicular Lymphoma
reuters.com · 1d ago
U.S. FDA Approves Yescarta® for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy
Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory follicular lymph...
Business Wire · 1d ago
Gilead Sciences Inc. stock outperforms market on strong trading day
marketwatch.com · 1d ago
Global CAR-T Cell Therapy Market Size, Shares, Trends, Strategies, Impacts, Status, Analysis and Forecast Report 2026
Mar 05, 2021 (Market Insight Reports) -- Selbyville, Delaware, MarketStudyReport.com offers report on Global CAR-T Cell Therapy Market that evaluates...
Market Insight Reports · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GILD. Analyze the recent business situations of Gilead Sciences through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 31 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GILD stock price target is 74.54 with a high estimate of 100.00 and a low estimate of 59.00.
EPS
Institutional Holdings
Institutions: 2.38K
Institutional Holdings: 1.03B
% Owned: 82.26%
Shares Outstanding: 1.26B
TypeInstitutionsShares
Increased
499
43.92M
New
333
379.42K
Decreased
674
50.78M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Chief Executive Officer/Director
Daniel O'Day
Chief Financial Officer/Executive Vice President
Andrew Dickinson
Executive Vice President/Chief Compliance Officer/General Counsel/Secretary
Brett Pletcher
Executive Vice President/Director of Human Resources
Katie Watson
Executive Vice President/Director of Human Resources
Jyoti Mehra
Senior Vice President
Linda Higgins
Senior Vice President
Michael Quigley
Other
Johanna Mercier
Other
Merdad Parsey
Lead Director/Independent Director
Kevin Lofton
Director
Jeffrey Bluestone
Director
Javier Rodriguez
Director
Anthony Welters
Independent Director
Jacqueline Barton
Independent Director
Sandra Horning
Independent Director
Kelly Kramer
Independent Director
Harish Manwani
Independent Director
Richard Whitley
Independent Director
Per Wold-Olsen
Declaration Date
Dividend Per Share
Ex-Div Date
02/04/2021
Dividend USD 0.71
03/12/2021
10/28/2020
Dividend USD 0.68
12/14/2020
07/30/2020
Dividend USD 0.68
09/14/2020
04/29/2020
Dividend USD 0.68
06/11/2020
02/03/2020
Dividend USD 0.68
03/12/2020
10/23/2019
Dividend USD 0.63
12/12/2019
07/29/2019
Dividend USD 0.63
09/12/2019
05/01/2019
Dividend USD 0.63
06/13/2019
02/01/2019
Dividend USD 0.63
03/14/2019
10/24/2018
Dividend USD 0.57
12/13/2018
07/24/2018
Dividend USD 0.57
09/13/2018
04/30/2018
Dividend USD 0.57
06/14/2018
02/05/2018
Dividend USD 0.57
03/15/2018
10/25/2017
Dividend USD 0.52
12/14/2017
07/25/2017
Dividend USD 0.52
09/14/2017
05/01/2017
Dividend USD 0.52
06/14/2017
02/06/2017
Dividend USD 0.52
03/14/2017
10/31/2016
Dividend USD 0.47
12/13/2016
07/22/2016
Dividend USD 0.47
09/14/2016
04/27/2016
Dividend USD 0.47
06/14/2016
02/02/2016
Dividend USD 0.43
03/14/2016
10/26/2015
Dividend USD 0.43
12/14/2015
07/23/2015
Dividend USD 0.43
09/14/2015
04/24/2015
Dividend USD 0.43
06/12/2015
  • All
  • Financials
  • Insiders
More
About GILD
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Webull offers kinds of Gilead Sciences, Inc. stock information, including NASDAQ:GILD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GILD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GILD stock methods without spending real money on the virtual paper trading platform.